ライフサイエンスコーパス: spleen tyrosine kinase

1 breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase).

2 hways that involved the mannose receptor and spleen tyrosine kinase.

3 (GS-9973) is an oral, selective inhibitor of spleen tyrosine kinase.

4 bulin-E crosslinking, it did not require the spleen tyrosine kinase.

5 ing protein 9 (CARD9) disturb the subsequent spleen tyrosine kinase 2-CARD9/BCL10/MALT1-driven signal

6 n an increase in tyrosine phosphorylation of spleen tyrosine kinase, a hallmark feature of the Dectin

7 mediator release, as well as Lyn kinase and spleen tyrosine kinase activation and signaling through

8 Dectin-1-mediated spleen tyrosine kinase activation is required for TLR9 t

9 s and controls phagosomal maturation through spleen tyrosine kinase activation.

10 ositol (4,5)-bisphosphate wave, and requires spleen tyrosine kinase activity.

11 n Dectin-1 pathway components phosphorylated spleen tyrosine kinase and caspase recruitment domain-co

12 compromised E-selectin-induced activation of spleen tyrosine kinase and cell adhesion to intercellula

13 ind to monocyte FcgammaRIIA, which activates spleen tyrosine kinase and leads to the generation of ti

14 activated VLA-4 adhesion via phosphorylated spleen tyrosine kinase and paxillin within focal adhesio

15 es the B-cell receptor (BCR)-related kinases spleen tyrosine kinase and phosphatidylinositol 3-kinase

16 differentiated osteoclasts are dependent on spleen tyrosine kinase and phospholipase Cgamma2 phospho

17 is in turn activates the Src family kinases, spleen tyrosine kinase and PLCgamma2, and platelet integ

18 Both the spleen tyrosine kinase and Raf-1 pathways were involved

19 ited upregulated tyrosine phosphorylation of spleen tyrosine kinase and several other signal transduc

20 atalytic interaction between the kinase Syk (spleen tyrosine kinase) and the substrate PLCgamma2 to e

21 ing the high-affinity IgE receptor subunits, spleen tyrosine kinase, and phospholipase C), production

22 eptor, differentially activate NF-kappaB and spleen tyrosine kinase, and stimulate the production of

23 ession of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT.

24 kinase inhibitors that target BCR signaling (spleen tyrosine kinase, Bruton tyrosine kinase, PI3Kdelt

25 ting of the B-cell receptor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine kinase, and ph

26 Several spleen tyrosine kinase-coupled C-type lectin receptors (

27 emerged that Dectin-1 is one of a number of spleen tyrosine kinase-coupled C-type lectin receptors t

28 ing reactive oxygen species, thus preventing spleen tyrosine kinase dephosphorylation and perpetuatin

29 Spleen tyrosine kinase expression was found in human and

30 rthermore, treatment of lymphocytes with the spleen tyrosine kinase family inhibitor piceatannol redu

31 f TULA-2 resulted in hyperphosphorylation of spleen tyrosine kinase following FcgammaRIIA activation

32 Inhibition of spleen tyrosine kinase has attracted much attention as a

33 Inhibition of spleen tyrosine kinase has attracted much attention as a

34 Spleen tyrosine kinase inhibition directly attenuates ai

35 with phosphatidylinositol 3-kinase delta and spleen tyrosine kinase inhibition, this phase 2 study ev

36 ion of albumin nanoparticles loaded with the spleen tyrosine kinase inhibitor, piceatannol, which blo

37 ivity to entospletinib, a recently developed spleen tyrosine kinase inhibitor.

38 imal B-cell receptor signaling pathway (e.g. spleen tyrosine kinase inhibitors and Bruton's tyrosine

39 Similarly to p38 inhibitors, current spleen tyrosine kinase inhibitors have not fulfilled the

40 identification of three series of selective spleen tyrosine kinase inhibitors that support our hypot

41 ture-guided optimization of pyridazine amide spleen tyrosine kinase inhibitors.

42 shown to result in an IL-2-inducible kinase-spleen tyrosine kinase (ITK-Syk) fusion transcript.

43 The inducible T cell kinase-spleen tyrosine kinase (ITK-SYK) oncogene consists of th

44 ession, CD203c expression, and intracellular spleen tyrosine kinase levels.

45 not PIP5K-alpha is transiently activated by spleen tyrosine kinase-mediated phosphorylation.

46 The activation of NLRP3 by heme required spleen tyrosine kinase, NADPH oxidase-2, mitochondrial r

47 suppressive cytokine IL-10 via the MyD88 and spleen tyrosine kinase pathways.

48 n used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, B

49 ivation via the SFK (Src family kinase)-Syk (spleen tyrosine kinase)-PLCgamma2 (phospholipase Cgamma2

50 ton's tyrosine kinase (pBtk), phosphorylated Spleen tyrosine kinase (pSyk), and nuclear receptor Nur7

51 of Bruton's tyrosine kinase, PI3Kdelta, and spleen tyrosine kinase) represent a significant therapeu

52 ng pathway that is dependent on FcRgamma and spleen tyrosine kinase, resulting in downregulation of i

53 roles in coordinating the signaling through spleen tyrosine kinase, Src family kinases, phosphatidyl

54 hly selective pharmacologic inhibitor of the spleen tyrosine kinase Syk [PRT060318; 2-((1R,2S)-2-amin

55 r differential molecular associations of the spleen tyrosine kinase Syk that preferentially binds to

56 grin, the Src family tyrosine kinase FGR and spleen tyrosine kinase SYK.

57 Spleen tyrosine kinase (Syk) activation is a key interme

58 The results show that spleen tyrosine kinase (Syk) activation, an early step i

59 inescence detection to the direct sensing of spleen tyrosine kinase (Syk) activity and inhibition usi

60 Antibody-mediated TREM2 stimulation enhanced spleen tyrosine kinase (SYK) activity and uptake of Stap

61 BCR signaling activates spleen tyrosine kinase (SYK) and downstream pathways inc

62 -CD14 selectively inhibits TLR4 endocytosis, spleen tyrosine kinase (Syk) and IRF3 phosphorylation, a

63 lex led to the recruitment and activation of spleen tyrosine kinase (Syk) and phosphatidylinositol-4,

64 /carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK.

65 vealed an increased basal phosphorylation of spleen tyrosine kinase (SYK) and phospholipase Cgamma2.

66 uction is strongly impaired by inhibitors of spleen tyrosine kinase (Syk) and PI3K.

67 ibition of SLE T cell activation by blocking spleen tyrosine kinase (Syk) and SLE T cell migration by

68 was necessary to sustain phosphorylation of spleen tyrosine kinase (SYK) and the B-cell linker prote

69 re upstream protein tyrosine kinases such as spleen tyrosine kinase (SyK) and the JAK family of kinas

70 lation of this tyrosine initiates binding of spleen tyrosine kinase (Syk) and triggers further downst

71 was abolished by pharmacological blockade of spleen tyrosine kinase (Syk) and was absent in Syk(-/-)

72 The spleen tyrosine kinase (Syk) and zeta-associated protein

73 vidence for a previously unknown function of spleen tyrosine kinase (SYK) as a partner and posttransl

74 Integrin-based activation of spleen tyrosine kinase (Syk) contributes to myeloid cell

75 Spleen tyrosine kinase (SYK) has an important role in im

76 Spleen tyrosine kinase (Syk) has been identified as an i

77 Spleen tyrosine kinase (Syk) has been implicated in a nu

78 Although spleen tyrosine kinase (SYK) has been implicated in hema

79 e sought to further evaluate the role of the spleen tyrosine kinase (Syk) in cGVHD in multiple murine

80 ssion of the intracellular signaling pathway spleen tyrosine kinase (Syk) in intestinal DCs from H. p

81 tagonizing the activities of RAF1, BRAF, and spleen tyrosine kinase (SYK) in normal B cells and CLL c

82 and colleagues describe the critical role of spleen tyrosine kinase (SYK) in paclitaxel resistance by

83 Inhibition of spleen tyrosine kinase (SYK) in tonic B-cell receptor (B

84 Spleen tyrosine kinase (Syk) induces cell survival and p

85 ort to the development of clinical trials of spleen tyrosine kinase (Syk) inhibition for more effecti

86 signaling pathway, PD98059 and U0126 and the spleen tyrosine kinase (Syk) inhibitor, Piceatannol.

87 by Siglec-1 was significantly attenuated by spleen tyrosine kinase (Syk) inhibitor.

88 n BMDCs from wild-type mice was inhibited by spleen tyrosine kinase (Syk) inhibitors and was abolishe

89 A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described.

90 pment of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable d

91 Spleen tyrosine kinase (Syk) initiates and amplifies the

92 Spleen tyrosine kinase (Syk) is a candidate tumor (metas

93 Spleen tyrosine kinase (SYK) is a candidate tumor suppre

94 Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine k

95 The cytoplasmic spleen tyrosine kinase (SYK) is a key regulator of signa

96 Spleen tyrosine kinase (Syk) is a non-receptor tyrosine

97 Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine k

98 Spleen tyrosine kinase (Syk) is a protein tyrosine kinas

99 Spleen tyrosine kinase (Syk) is an attractive drug targe

100 Spleen tyrosine kinase (Syk) is an important modulator o

101 Spleen tyrosine kinase (Syk) is an intracellular nonrece

102 Spleen tyrosine kinase (SYK) is an intracellular protein

103 Spleen tyrosine kinase (Syk) is important for Fc and B-c

104 Spleen tyrosine kinase (Syk) is involved in membrane-med

105 Spleen tyrosine kinase (Syk) is involved in the activati

106 Here we show that spleen tyrosine kinase (SYK) is upregulated during brown

107 ruitment in A. fumigatus phagosomes required spleen tyrosine kinase (Syk) kinase-dependent production

108 al numbers, exhibited unimpaired BCR-induced spleen tyrosine kinase (Syk) phosphorylation but reduced

109 The spleen tyrosine kinase (Syk) plays a central role in the

110 of Mule phosphorylation by silencing of the Spleen Tyrosine Kinase (Syk) prevents its dissociation f

111 Spleen tyrosine kinase (Syk) promotes leukocyte recruitm

112 ctivation, as inhibition of the BCR-proximal spleen tyrosine kinase (SYK) reversed ERK hyperactivatio

113 We show that mmLDL induced recruitment of spleen tyrosine kinase (Syk) to a TLR4 signaling complex

114 1, a C-type lectin receptor that signals via spleen tyrosine kinase (Syk) to induce ROS.

115 rior to this, DENV immune complexes activate spleen tyrosine kinase (Syk) within 1 hpi.

116 The spleen tyrosine kinase (Syk), a key component of BCR sig

117 M), leading to recruitment and activation of spleen tyrosine kinase (Syk), a kinase that is essential

118 Spleen tyrosine kinase (Syk), a nonreceptor protein kina

119 In the present study, we concentrate on Spleen tyrosine kinase (Syk), a nonreceptor tyrosine kin

120 In this report, we assessed the role of spleen tyrosine kinase (SYK), a nonreceptor tyrosine kin

121 was applied to identify unique substrates of spleen tyrosine kinase (Syk), a protein-tyrosine kinase

122 Spleen tyrosine kinase (Syk), an immunoregulatory kinase

123 cellular signaling proteins FcepsilonRgamma, spleen tyrosine kinase (SYK), and EWS/FLI1-Activated Tra

124 Ks), DAP12 and Fc receptor-gamma (FcRgamma), spleen tyrosine kinase (Syk), and p38.

125 conjunction with Src family kinases (SFKs), spleen tyrosine kinase (Syk), and phospholipase gamma2 (

126 IL-21 activated spleen tyrosine kinase (Syk), as evidenced by its abilit

127 sphotyrosinylation and specifically recruits spleen tyrosine kinase (Syk), initiating cellular activa

128 dothelial selectins activate Src kinases and spleen tyrosine kinase (Syk), leading to alpha(L)beta(2)

129 tment of early signaling proteins, including spleen tyrosine kinase (Syk), linker for activation of T

130 macrophages and dendritic cells deficient in spleen tyrosine kinase (Syk), we identified a novel path

131 ITAM) phosphorylation, and activation of the spleen tyrosine kinase (SYK), which initiates downstream

132 We identified spleen tyrosine kinase (Syk), which is activated by oxid

133 hematosus (SLE) display increased amounts of spleen tyrosine kinase (Syk), which is involved in the a

134 s phosphorylation induces the recruitment of spleen tyrosine kinase (Syk), which is required for down

135 Additionally, macrophages deficient in spleen tyrosine kinase (Syk), which signals downstream o

136 ell antigen receptor (BCR)-proximal effector spleen tyrosine kinase (SYK), which we identified as an

137 was TLR2-independent, involved sarcoma (SRC)-spleen tyrosine kinase (SYK)-Caspase recruitment domain-

138 up-regulated in GBM tissue samples through a spleen tyrosine kinase (SYK)-dependent activation of the

139 ymphoblastic leukemia (ALL) by targeting the spleen tyrosine kinase (SYK)-dependent antiapoptotic bla

140 erful platelet activation through a Src- and spleen tyrosine kinase (Syk)-dependent tyrosine phosphor

141 beta by fine-tuning pro-IL-1beta expression, spleen tyrosine kinase (SYK)-mediated NLRP3 activation a

142 bl family kinases is mediated in part by the spleen tyrosine kinase (Syk).

143 ent on FcgammaR signaling events mediated by spleen tyrosine kinase (Syk).

144 a novel association of CD36 with VEGFR-2 and spleen tyrosine kinase (Syk).

145 -competitive inhibitor of the BCR-associated spleen tyrosine kinase (SYK).

146 on-associated antigen-1 by signaling through spleen tyrosine kinase (Syk).

147 rolling on P-selectin, and to signal through spleen tyrosine kinase (Syk).

148 eraction with TLR2 or by directly activating spleen tyrosine kinase (Syk).

149 novel target for curcumin in B lymphoma viz spleen tyrosine kinase (Syk).

150 rc homology phosphatase-1 to dephosphorylate spleen tyrosine kinase (Syk).

151 ine revealed that this compound inhibits the spleen tyrosine kinase (Syk).

152 llular redistribution with F-actin by way of spleen tyrosine kinase (SYK).

153 ased on the activity of SHP1 phosphatase and spleen tyrosine kinase (Syk).

154 atosus (SLE) express increased levels of the spleen tyrosine kinase (Syk).

155 ed by the equilibrium between kinases (e.g., spleen tyrosine kinase [Syk]) and phosphatases (e.g., Sh

156 META060 inhibited the activity of kinases (spleen tyrosine kinase [Syk], Bruton's tyrosine kinase [

157 signaling nodes (Src family tyrosine kinase, spleen tyrosine kinase [SYK], phospholipase Cgamma), but

158 Because spleen tyrosine kinase, Syk, is an upstream kinase in mu

159 contrast, levels of IgE receptor-associated spleen tyrosine kinase, Syk, were increased on day 4 (P

160 tream of CD18 integrins are dependent on the spleen tyrosine kinase, Syk.

161 or macrophages treated with an inhibitor of spleen tyrosine kinase, the tyrosine kinase that signals